III期临床试验-话题@MedSci

#III期临床试验#

101篇内容 | 2165人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1588010, encodeId=5a5215880109a, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=73, createdTime=2018-10-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588009, encodeId=4b51158800942, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=47, createdTime=2018-09-27, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588008, encodeId=7dfd1588008a0, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=71, createdTime=2018-07-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588007, encodeId=25a4158800eed, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=63, createdTime=2018-04-30, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588006, encodeId=d13e158800632, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=33, createdTime=2018-04-17, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588005, encodeId=34521588005f0, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=108, createdTime=2018-01-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588004, encodeId=9ba6158800408, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=55, createdTime=2018-01-12, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588003, encodeId=15981588003b9, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=34, createdTime=2018-01-02, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588002, encodeId=3040158800232, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=0, createdTime=2017-11-19, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588001, encodeId=b4d715880019e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=85, createdTime=2016-12-28, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588000, encodeId=e467158800064, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, objectType=article, longId=56018, objectId=86745601843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86745601843, replyNumber=0, likeNumber=37, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86745601843, moduleTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86745601843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587999, encodeId=6030158e99923, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=86, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587998, encodeId=d331158e998c3, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, objectType=article, longId=55622, objectId=6995556228c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6995556228c, replyNumber=0, likeNumber=33, createdTime=2015-09-03, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6995556228c, moduleTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6995556228c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587997, encodeId=b70e158e997cf, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, objectType=article, longId=45947, objectId=66654594e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66654594e34, replyNumber=0, likeNumber=62, createdTime=2015-01-23, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66654594e34, moduleTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66654594e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587996, encodeId=1a49158e99610, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, objectType=article, longId=45906, objectId=c85f4590698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c85f4590698, replyNumber=0, likeNumber=32, createdTime=2015-01-23, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c85f4590698, moduleTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c85f4590698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587995, encodeId=73e3158e995c8, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, objectType=article, longId=40850, objectId=966c408506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=966c408506a, replyNumber=0, likeNumber=68, createdTime=2014-10-02, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=966c408506a, moduleTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966c408506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587994, encodeId=8fba158e9943b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, objectType=article, longId=37049, objectId=a8b93e049a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b93e049a1, replyNumber=0, likeNumber=35, createdTime=2014-06-27, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b93e049a1, moduleTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b93e049a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587993, encodeId=0907158e993bf, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动, objectType=article, longId=36188, objectId=2cdb361889b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdb361889b, replyNumber=0, likeNumber=89, createdTime=2014-06-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdb361889b, moduleTitle=BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cdb361889b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587992, encodeId=268d158e9923e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, objectType=article, longId=30355, objectId=46a930355d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a930355d0, replyNumber=0, likeNumber=31, createdTime=2014-02-10, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a930355d0, moduleTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a930355d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=阿斯利康旗下三个靶向肿瘤药物进入III期临床试验, objectType=article, longId=19185, objectId=10d619185bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10d619185bd, replyNumber=0, likeNumber=61, createdTime=2013-05-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10d619185bd, moduleTitle=阿斯利康旗下三个靶向肿瘤药物进入III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10d619185bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床试验

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2018-10-25

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2018-09-27

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2018-07-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Vertex在III期临床试验中测试CF三联疗法

2018-04-30

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-04-17

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Teva的皮下哮喘药物在III期临床试验中失败

2018-01-25

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-01-12

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-01-02

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2017-11-19

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2016-12-28

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段

2015-09-03

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观

2015-01-23

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想

2015-01-23

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

汤森路透：五个进入III期临床试验的更具前景药物品种

2014-10-02

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果

2014-06-27

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动

2014-06-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败

2014-02-10

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

阿斯利康旗下三个靶向肿瘤药物进入III期临床试验

2013-05-25

科室
- - 订阅+
  - 更多科室
工具
服务